Results 71 to 80 of about 6,178 (191)

Co(II) és szulfonált deferasirox származékok közötti kölcsönhatások oldategyensúlyi vizsgálata

, 2020
A rákellenes kutatások középpontjába kerültek az ún. hipoxia-aktivált vegyületek, ugyanis a tumoros sejtekben, az érhálózat nem megfelelő kiépülése miatt oxigénhiányos állapot alakul ki, ami terápiás célpontként használható.
Nyujtó, Nikolett
core  

In vitro Studying of Deferasirox Side effects on the Structure and the Function of Bovine Liver Catalase [PDF]

Journal of Fasa University of Medical Sciences, 2014
Background & Objective: Oral chelators such as deferasirox are used to treat iron overload caused by blood transfusion. Considering the significant role of liver in detoxification and drug metabolism as well as the importance of catalase as a key enzyme ...
Maryam Moradi, Adeleh Divsalar, Maryam Saidifar, Ali Akbar Saboury, Mohammad Tahmaseb   +4 more
doaj   +1 more source

Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload

Haematologica, 2006
BACKGROUND AND OBJECTIVES: Iron accumulation is an inevitable consequence of chronic blood transfusions and results in serious complications in the absence of chelation treatment to remove excess iron.
A Piga, R Galanello, GL Forni, MD Cappellini, R Origa, A Zappu, G Donato, E Bordone, A Lavagetto, L Zanaboni, R Sechaud, N Hewson, JM Ford, H Opitz, D Alberti   +14 more
doaj  

Efficacy and safety of deferasirox in pediatric patients of thalassemia at a Tertiary Care Teaching Hospital

Indian Journal of Medical and Paediatric Oncology, 2017
Objective: To evaluate efficacy, safety and utilization pattern of deferasirox in paediatric patients of transfusion dependant β Thalassemia Major at a tertiary care teaching hospital in Gujarat.
Dhaval R Thakor, Chetna K Desai, Jigar D Kapadia, Ram K Dikshit, K M Mehariya   +4 more
doaj   +1 more source

Comparison of Efficacy, Safety, and Humanistic Outcomes of Iron-Chelation Therapy in Pediatrics Suffering from Transfusion-Dependent β-Thalassemia Major

Indian Journal of Medical Specialities, 2020
Introduction: Beta-thalassemia major (β-TM) is a severe form of genetic disorder that affects the patient's quality of life. Iron-chelation therapy (ICT) is recommended in these patients to reduce the complications (iron overload) associated with ...
Narayana Goruntla, P. Stephen Azarya, Mahitha Chalagundla, Dasaratha Ramaiah Jinka, Pradeepkumar Bhupalam, Vishnuvandana Bandaru   +5 more
doaj   +1 more source

Synthese und Metallkomplexbildung von wasserlöslichen Derivaten des Eisen-Chelatkomplexbildners Deferasirox

, 2012
A water soluble model of deferasirox, 2-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzene-1,4-disulfonic acid (DSA), was prepared and characterised.
Koch, Nadine Jane
core   +1 more source

Corrigendum

ClinicoEconomics and Outcomes Research, 2011
York Zoellner1, Maria-Magdalena Balp2, Andrea Gili Marco21Hamburg University of Applied Sciences, Hamburg, Germany; 2Novartis Pharma AG, Basel, SwitzerlandThe role of galenic innovation in improving treatment compliance and persistence: three case ...
Zoellner Y, Balp MM, Gili Marco A
doaj  

A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan

Journal of the Formosan Medical Association, 2013
The newly available iron chelator deferasirox (Exjade, Novartis) is expected to provide better long-term clinical outcomes and improved quality of life for patients with thalassemia than its predecessor, deferoxamine (Desferal, Novartis), because of its ...
Wan-Ling Ho, Kuo-Piao Chung, Szu-Sheng Yang, Meng-Yao Lu, Shiann-Tarng Jou, Hsiu-Hao Chang, Yung-Li Yang, Dong-Tsamn Lin, Kai-Hsin Lin   +8 more
doaj   +1 more source

Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 510-519, August 2026.
Genetic variation contributes substantially to interindividual and interpopulation differences in drug response, yet most pharmacogenomic studies remain biased toward European populations. Here, we systematically assessed pharmacogenomic variation across East Asians (EAS) and Europeans (EUR) using public genomic datasets and investigated the potential ...
Sihan Chen, Hongpu Chen, Shuhua Xu
wiley   +1 more source

Fluorofórt is tartalmazó Co(III) kompexek előállítása és vizsgálata

, 2018
A reduktív környezetben aktiválódó fémkomplex prodrugok használatával lehetségessé válhat a rákos sejtek kezelése. A konfokális mikroszkópia lehetőve teszi, fluorofór ligandumok használatával követhető a gyógyszermolekula sejtbe jutása, sejten belüli ...
Vas, Péter Mihály
core